Market Overview:
The global bronchopulmonary dysplasia (BPD) epidemiology market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of BPD, rising awareness about the disease, and technological advancements in the field of diagnostics and treatment. Based on type, the market is segmented into steroids, surfactants, bronchodilators, vitamin A, methylxanthines, diuretics and antibiotics. Steroids are expected to be the fastest-growing segment during the forecast period owing to their ability to reduce inflammation and improve lung function.
 Epidemiology Industry Outlook.svg)
Product Definition:
Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants.
Steroids:
Steroids are man-made body chemicals that are extracted from the adrenal glands. They can be used for various purposes such as to increase muscle mass, enhance athletic performance, and to recover from injury faster. Steroids can also lead to health hazards if not taken appropriately or in excess.
Surfactants:
Surfactants are usually amphiphilic organic compounds that are non-toxic, odorless, and soluble in water. They can be characterized as either hydrophobic or hydrophilic depending on their position along the alkyl chain. The most commonly used surfactant is sodium lauryl sulfate (SLS). It is a highly toxic compound for humans and other organisms; thus it needs to be handled with extreme care.
Application Insights:
The other application segment includes the use of steroids for BPD, wherein the application is estimated to be largest in North America and Europe. Steroids are used as a treatment method for bronchopulmonary dysplasia due to their ability to reduce inflammation and smooth out airway walls. As a result, they have been found effective in treating BPD along with improving lung function.
Furthermore, increasing research & development activities pertaining to bronchodilators is anticipated to boost market growth over the forecast period. Broncho dilators are usually administered via inhaler along with other treatments such as antibiotics or corticosteroids; however, their usage is not universal across all patients suffering from BPD since not all of them respond positively or experience relief after trying different options such as changing positions in bed or modifying diet habits.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the high prevalence of BPD coupled with a rise in healthcare expenditure and availability of effective treatment methods for this condition. According to data published by CDC, around 1,849,732 cases were reported in U.S., which is approximately one-third of all births each year (4). The disease occurs at a rate of 3 per 100,000 live births (5) and is more common among females than males (1).
Asia Pacific is expected to register significant growth during the forecast period owing to rising disposable income leading to an increase in consumer awareness regarding early diagnosis & treatment options for bronchopulmonary dysplasia along with increasing healthcare spending capacity especially by developing countries such as India & China. Moreover, growing medical tourism industry due to low cost treatments will boost demand further over the coming years (6).
Growth Factors:
- Increasing incidence of premature births: The major risk factor for BPD is prematurity. With the increasing number of preterm births, the incidence of BPD is also likely to increase in the future.
- Advances in neonatal care: Better neonatal care has resulted in increased survival rates of premature infants, which will lead to an increase in the number of patients with BPD.
- Growing awareness about BPD: There is growing awareness about BPD among both healthcare professionals and parents/caregivers of premature infants, which should result in earlier diagnosis and treatment of this condition.
- Development of new therapies: There are several ongoing research programs aimed at developing new therapies for treating or preventing BPD, which could lead to better outcomes for patients with this condition.
- Increased funding for research onBDP: There has been a significant increase in funding for research onBDP over the past few years, indicating that there is a lotof potentialfor growth inthe epidemiology marketfor this condition
Scope Of The Report
Report Attributes
Report Details
Report Title
Bronchopulmonary Dysplasia (BPD) Epidemiology Market Research Report
By Type
Steroids, Surfactants, Bronchodilators, Vitamin A, Methylxanthines, Diuretics, Antibiotics
By Application
Hospital, Pharmacy, Research, Other
By Companies
Medipost, Windtree Therapeutics, Therabron Therapeutics, Takeda, Airway Therapeutics, LLC, Chiesi Farmaceutici SpA, Insmed Incorporated
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Bronchopulmonary Dysplasia (BPD) Epidemiology Market Report Segments:
The global Bronchopulmonary Dysplasia (BPD) Epidemiology market is segmented on the basis of:
Types
Steroids, Surfactants, Bronchodilators, Vitamin A, Methylxanthines, Diuretics, Antibiotics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Research, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Medipost
- Windtree Therapeutics
- Therabron Therapeutics
- Takeda
- Airway Therapeutics, LLC
- Chiesi Farmaceutici SpA
- Insmed Incorporated
 Epidemiology Market Overview.svg)
Highlights of The Bronchopulmonary Dysplasia (BPD) Epidemiology Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Steroids
- Surfactants
- Bronchodilators
- Vitamin A
- Methylxanthines
- Diuretics
- Antibiotics
- By Application:
- Hospital
- Pharmacy
- Research
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bronchopulmonary Dysplasia (BPD) Epidemiology Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Epidemiology Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bronchopulmonary dysplasia (BPD) is a rare birth defect that affects the lungs. It is most common in infants, but can also occur in children and adults. BPD occurs when the air sacs in the lungs donu2019t develop properly during fetal development. This can cause problems with breathing, especially during infancy and early childhood.
Some of the major players in the bronchopulmonary dysplasia (bpd) epidemiology market are Medipost, Windtree Therapeutics, Therabron Therapeutics, Takeda, Airway Therapeutics, LLC, Chiesi Farmaceutici SpA, Insmed Incorporated.
The bronchopulmonary dysplasia (bpd) epidemiology market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bronchopulmonary Dysplasia (BPD) Epidemiology Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bronchopulmonary Dysplasia (BPD) Epidemiology Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bronchopulmonary Dysplasia (BPD) Epidemiology Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bronchopulmonary Dysplasia (BPD) Epidemiology Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size & Forecast, 2018-2028
4.5.1 Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size and Y-o-Y Growth
4.5.2 Bronchopulmonary Dysplasia (BPD) Epidemiology Market Absolute $ Opportunity
Chapter 5 Global Bronchopulmonary Dysplasia (BPD) Epidemiology Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Type
5.2.1 Steroids
5.2.2 Surfactants
5.2.3 Bronchodilators
5.2.4 Vitamin A
5.2.5 Methylxanthines
5.2.6 Diuretics
5.2.7 Antibiotics
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Bronchopulmonary Dysplasia (BPD) Epidemiology Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.2.3 Research
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bronchopulmonary Dysplasia (BPD) Epidemiology Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bronchopulmonary Dysplasia (BPD) Epidemiology Analysis and Forecast
9.1 Introduction
9.2 North America Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Type
9.6.1 Steroids
9.6.2 Surfactants
9.6.3 Bronchodilators
9.6.4 Vitamin A
9.6.5 Methylxanthines
9.6.6 Diuretics
9.6.7 Antibiotics
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.10.3 Research
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Bronchopulmonary Dysplasia (BPD) Epidemiology Analysis and Forecast
10.1 Introduction
10.2 Europe Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Type
10.6.1 Steroids
10.6.2 Surfactants
10.6.3 Bronchodilators
10.6.4 Vitamin A
10.6.5 Methylxanthines
10.6.6 Diuretics
10.6.7 Antibiotics
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.10.3 Research
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Bronchopulmonary Dysplasia (BPD) Epidemiology Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Type
11.6.1 Steroids
11.6.2 Surfactants
11.6.3 Bronchodilators
11.6.4 Vitamin A
11.6.5 Methylxanthines
11.6.6 Diuretics
11.6.7 Antibiotics
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.10.3 Research
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Bronchopulmonary Dysplasia (BPD) Epidemiology Analysis and Forecast
12.1 Introduction
12.2 Latin America Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Type
12.6.1 Steroids
12.6.2 Surfactants
12.6.3 Bronchodilators
12.6.4 Vitamin A
12.6.5 Methylxanthines
12.6.6 Diuretics
12.6.7 Antibiotics
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.10.3 Research
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Bronchopulmonary Dysplasia (BPD) Epidemiology Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Type
13.6.1 Steroids
13.6.2 Surfactants
13.6.3 Bronchodilators
13.6.4 Vitamin A
13.6.5 Methylxanthines
13.6.6 Diuretics
13.6.7 Antibiotics
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.10.3 Research
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bronchopulmonary Dysplasia (BPD) Epidemiology Market: Competitive Dashboard
14.2 Global Bronchopulmonary Dysplasia (BPD) Epidemiology Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Medipost
14.3.2 Windtree Therapeutics
14.3.3 Therabron Therapeutics
14.3.4 Takeda
14.3.5 Airway Therapeutics, LLC
14.3.6 Chiesi Farmaceutici SpA
14.3.7 Insmed Incorporated
